Study with Reslizumab in Patients With Severe Eosinophilic Asthma
Study Title
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Teva Identifier
- C38072-AS-30066 | 2016-004661-23
ClinicalTrials.gov Identifier
- NCT03052725
Study Status
- Terminated
Trial Condition(s)
- Eosinophils, Asthma
Interventions
- Drug: reslizumab
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 12 Years and older
Trial Duration
- March 10, 2017 - February 22, 2018
Phase
- Phase 3
Study Type
Interventional
